Jane Mbui
YOU?
Author Swipe
View article: Assessment of a decentralization model in improving treatment and care of visceral leishmaniasis in Turkana County, Kenya: A mixed method study
Assessment of a decentralization model in improving treatment and care of visceral leishmaniasis in Turkana County, Kenya: A mixed method study Open
Background Visceral Leishmaniasis (VL) is a vector-borne disease caused by the protozoa Leishmania and transmitted by sandflies. Up to 60% of all VL cases worldwide occur in East Africa. Given its ranking as a main cause of death among the…
View article: Barriers and facilitators of care among visceral leishmaniasis patients following the implementation of a decentralized model in Turkana County, Kenya
Barriers and facilitators of care among visceral leishmaniasis patients following the implementation of a decentralized model in Turkana County, Kenya Open
Turkana County is among the eleven counties in Kenya endemic for Visceral Leishmaniasis (VL). Early diagnosis and management is crucial to improving quality of life, reducing related morbidity and mortality, and disease transmission. In Tu…
View article: Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa
Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa Open
Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to disease-specific variations in absorption, distribution…
View article: Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model
Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model Open
Background With the current treatment options for visceral leishmaniasis (VL), recrudescence of the parasite is seen in a proportion of patients. Understanding parasite dynamics is crucial to improving treatment efficacy and predicting pat…
View article: PA-682 Overcoming diverse challenges associated with innovative multicountry collaborative initiatives: the Kenyan experience of the Prev_PKDL project
PA-682 Overcoming diverse challenges associated with innovative multicountry collaborative initiatives: the Kenyan experience of the Prev_PKDL project Open
Background The EDCTP-funded PREV_PKDL project was designed to: i) advance the clinical development of a vaccine for prevention of visceral leishmaniasis (VL)/post kala azar dermal leishmaniasis (PKDL) and ii) to gain a greater understandin…
View article: Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis Open
Objectives To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated. As the majority of patients affected by VL are children…
View article: Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial Open
INTRODUCTION The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. Current treatment for VL comprises the combination of sodi…
View article: Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial Open
Background This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. Methods An open-labe…
View article: Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa Open
Background To expedite the development of new oral treatment regimens for visceral leishmaniasis (VL), there is a need for early markers to evaluate treatment response and predict long-term outcomes. Methods Data from 3 clinical trials wer…
View article: Association of Substance Use and Gender Based Violence among Students in a Tertiary Institution in Kakamega County, Kenya
Association of Substance Use and Gender Based Violence among Students in a Tertiary Institution in Kakamega County, Kenya Open
Background: Substance use among college and university students remains an important area of research due to the implications of early substance dependence on the future of the youth. Prior studies from various settings indicate relatively…
View article: Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa Open
Background Conventional miltefosine dosing (2.5 mg/kg/day) for treatment of visceral leishmaniasis (VL) is less effective in children than in adults. A higher allometric dose (median 3.2 mg/kg/day) was therefore investigated in paediatric …
View article: Urine-based antigen detection assay for diagnosis of visceral leishmaniasis using monoclonal antibodies specific for six protein biomarkers of Leishmania infantum / Leishmania donovani
Urine-based antigen detection assay for diagnosis of visceral leishmaniasis using monoclonal antibodies specific for six protein biomarkers of Leishmania infantum / Leishmania donovani Open
The development of an accurate protein-based antigen detection assay for diagnosis of active visceral leishmaniasis (VL) would represent a major clinical advance. VL is a serious and fatal disease caused by the parasites Leishmania infantu…
View article: Patient costs of diabetes mellitus care in public health care facilities in Kenya
Patient costs of diabetes mellitus care in public health care facilities in Kenya Open
Summary Objective To estimate the direct and indirect costs of diabetes mellitus care at five public health facilities in Kenya. Methods We conducted a cross‐sectional study in two counties where diabetes patients aged 18 years and above w…
View article: Diagnostic Accuracy of Unattended Automated Office Blood Pressure Measurement in Screening for Hypertension in Kenya
Diagnostic Accuracy of Unattended Automated Office Blood Pressure Measurement in Screening for Hypertension in Kenya Open
Despite increasing adoption of unattended automated office blood pressure (uAOBP) measurement for determining clinic blood pressure (BP), its diagnostic performance in screening for hypertension in low-income settings has not been determin…
View article: Development of a Multiplexed Assay for Detection of <i>Leishmania donovani</i> and <i>Leishmania infantum</i> Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis
Development of a Multiplexed Assay for Detection of <i>Leishmania donovani</i> and <i>Leishmania infantum</i> Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis Open
Visceral leishmaniasis (VL) is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani . The gold standard diagnostic test for VL is the demonstration of parasites or their DNA in spleen, lymph node,…
View article: Patient costs of hypertension care in public health care facilities in Kenya
Patient costs of hypertension care in public health care facilities in Kenya Open
Summary Background Hypertension in low‐ and middle‐income countries, including Kenya, is of economic importance due to its increasing prevalence and its potential to present an economic burden to households. In this study, we examined the …
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial Open
Background Convenient, safe, and effective treatments for visceral leishmaniasis in Eastern African children are lacking. Miltefosine, the only oral treatment, failed to achieve adequate efficacy, particularly in children, in whom linear d…
View article: Stroke Mortality in Kenya’s Public Tertiary Hospitals: A Prospective Facility-Based Study
Stroke Mortality in Kenya’s Public Tertiary Hospitals: A Prospective Facility-Based Study Open
Background: Despite the increasing global burden of stroke, there are limited data on stroke from Kenya to guide in decision-making. Stroke occurrence in sub-Saharan Africa has been associated with poor health outcomes. This study sought t…
View article: Stroke distribution patterns and characteristics in Kenya’s leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral Hospital
Stroke distribution patterns and characteristics in Kenya’s leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral Hospital Open
To our knowledge this is the first pilot demonstration establishing a stroke registry in sub-Saharan Africa and clearly establishes feasibility for this approach. It also has utility to both inform and potentially guide public policy and p…